Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51

2 Nov 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25467108
DOI: 10.1016/j.ctrv.2014.10.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51PMID 25467108Read ↗

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges AheadSemantic proximity Read ↗

Regulation and pharmacological targeting of RAD51 in cancerSemantic proximity Read ↗

New RAD51 Inhibitors to Target Homologous Recombination in Human CellsSemantic proximity Read ↗

Variation in RAD51 details a hub of functions: opportunities to advance cancer diagnosis and therapySemantic proximity Read ↗

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trialSemantic proximity Read ↗

miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axisSemantic proximity Read ↗

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cellsSemantic proximity Read ↗

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.Semantic proximity Read ↗

RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid TumorsSemantic proximity Read ↗

A cell-penetrating antibody inhibits human RAD51 via direct binding.Semantic proximity Read ↗

Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cellsSemantic proximity Read ↗

Systematic Screen Identifies miRNAs That Target RAD51 and RAD51D to Enhance ChemosensitivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.